CiiTA, LLC Company Blog

Welcome to the CiiTA, LLC company blog – your resource for judicious, topical information related to the PHS 340B Drug Pricing Program. At CiiTA, we believe 340B is a critical part of the United States’ healthcare safety net, and as it experiences unprecedented and relatively unchallenged growth, we labor to stay ahead of the curve so that we can continue to teach our clients what even they don’t know that they don’t know. Our portfolio of services and products are designed around sustaining the 340B Program while mitigating untoward behavior within the program.

CiiTA focuses exclusively on the manufacturer and their participation in the 340B Program. We are outspoken about protecting the 340B Program by making it sustainable and transparent. To that end, this blog will bring you all the news and emerging policies about the program.

CiiTA won’t shy away from controversial subject matters if that information helps protect the vitality of the program. You’ll find our articles are frank, meticulously fact-checked, and occasionally funny or irreverent. In any case, you will always know the difference between our opinions – which are emboldened by over 12 years of direct Covered Entity management – and fact. CiiTA offers unparalleled expertise in the 340B Program, and we’re happy to be able to pass our knowledge onto you, our associates in pharma, biotech, and blood products who are looking for value-based advice and information on the 340B Program’s continued expansion.

To view more info about our knowledge and perspectives on the 340B Program, please be sure to also visit our 340B Insights page.